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OBJECTIVES: Acute promyelocytic leukemia (APL) is a distinct subtype of acute mye-
loid leukemia (AML) with approximately 1,000 to 1,500 new cases diagnosed each 
year in the United States (US). Trisenox (arsenic trioxide, ATO) is currently licensed 
for the treatment of patients with APL who are refractory to, or have relapsed from 
previous treatment with all-trans retinoic acid (ATRA) and anthracycline-based 
chemotherapy. This analysis evaluated the cost-effectiveness of ATO+ATRA in 
the treatment of newly diagnosed low-to-intermediate risk APL in adult patients, 
compared to two other widely used regimens: ATRA+Ara-C+chemotherapy, and 
ATRA+Idarubicin (AIDA). Cost-effectiveness was measured as incremental cost 
per quality-adjusted life year (QALY) gained and per incremental cost per life year 
(LY) saved from a third-party payer perspective in the US. METHODS: A Markov 
cohort model with monthly cycles and four health states (1st-line stable disease, 
2nd-line stable disease, 2nd-line disease event, and dead) was developed. Patients 
in the model begin treatment at age 45 and were followed until death. Eight 
months duration of ATO+ATRA was compared to either 15 months of ATRA+Ara-
C+chemotherapy or 33 months of AIDA. Efficacy data (event-free survival.overall 
survival) were obtained from key clinical trials. Quality of life/health utility data 
were obtained from the literature. Costs were obtained from standard US data 
sources. Transition probabilities were estimated by calibrating the model to event-
free and overall survival Kaplan-Meier curves for each treatment. Deterministic 
and probabilistic sensitivity analyses were conducted. RESULTS: Compared to 
ATRA+Ara-C+chemotherapy, ATO+ATRA had incremental cost effectiveness ratios 
of $5,900/QALY gained and $4,800/LY saved. ATO+ATRA weakly dominated AIDA 
(had a lower incremental cost-effectiveness ratio and more QALYs and LYs) in newly 
diagnosed patients. The results were robust to sensitivity analysis. CONCLUSIONS: 
The shorter and better-tolerated regimen of ATO+ATRA is a highly cost-effective 
strategy compared to ATRA+Ara-C+chemotherapy or AIDA in the treatment of newly 
diagnosed low-to-intermediate risk APL patients.
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OBJECTIVES: In ALSYMPCA, radium-223+BSoC significantly prolonged overall sur-
vival by 3.6 months (HR= 0.70; 95% CI, 0.58-0.83; P< 0.001). Analysis of prospectively 
collected medical resource utilization (MRU) data from ALSYMPCA demonstrated 
that radium-223+BSoC vs BSoC reduced overall MRU, including number of hospi-
talization days/patient/year (8.1 vs 14.6; P< 0.001). An existing cost-effectiveness 
analysis (CEA) model was modified by incorporating the prospective MRU data 
from ALSYMPCA to evaluate their effect on estimated cost-effectiveness of radium-
223+BSoC vs placebo+BSoC in Canada. METHODS: A Markov model was developed 
with 5 health states, reflecting disease progression and SSEs. The Canadian payer 
perspective was used. Quality of life data were from ALSYMPCA; cost inputs were 
from recognized Canadian sources. Costs and outcomes were discounted at a 5% 
annual rate. Model time horizon was 5 years. RESULTS: Incorporating MRU data 
reduced the incremental cost estimate by $11,065 relative to CEA without MRU data 
and improved the incremental cost-effectiveness ratio for radium-223+BSoC vs 
placebo+BSoC by ~35% to $73,408 ($20,098 incremental cost, 0.274 quality-adjusted 
life years [QALYs] gained), substantially lower than the frequently referenced, 
although not explicitly stated, Canadian cancer drug threshold ($100,000/QALY). 
Sensitivity analyses demonstrated robustness of cost-effectiveness results. Patient 
management costs were affected primarily by differential hospital utilization 
between treatment groups. CONCLUSIONS: Including directly observed MRU data 
in this model markedly improved the impact of radium-223 vs modeled benefits 
alone, confirming its cost-effectiveness as a treatment for CRPC with symptomatic 
bone metastases and no visceral metastases. Reduced hospital utilization with 
radium-223 may be driven by delays in time to symptomatic skeletal event (SSE) 
and reduced hospitalization days/patient/year after SSE (Cislo et al. ASCOQCS 2014).
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OBJECTIVES: To evaluate cost-effectiveness of different HPV vaccination as alterna-
tives or additions to the current screening program to prevent and control cervical 
cancer in Mainland China. METHODS: A Markov model was developed for a cohort 
of 100,000 12-year-old girls to simulate the natural history of low risk and high risk 
to HPV infection and its progress to cervical cancer or genital warts. Three recom-
mended screening (protocol 1. Liquid-based cytology test + HPV DNA test; protocol 
2. Pap smear cytology test + HPV DNA test; protocol 3. Visual inspection with acetic 
acid) and two types of HPV vaccination programs (bivalent and quadrivalent vac-
cines) were incorporated to the two kinds of HPV vaccines. Input data were obtained 
from literature review, national databases, and a field study. Sensitivity analyses 
tive. METHODS: We compared ipilimumab treatment for advance melanoma 
with other drugs for advanced cancer that met inclusion criteria including: (1) 
positive phase three study with overall survival as primary or secondary aim, 
(2) authorized by Chilean government agency, and (3) verifiable price in the pri-
vate market. We performed a cost – efficacy analysis, using local prices obtained 
from published local sources to calculate an average cost to progression. Time to 
progression was obtained from published clinical trials. Mean overall survival 
improvement was used as the efficacy metric. Cost – efficacy outputs were plot-
ted and compared. All costs are presented in 2014 USD. Additionally, a survey to 
Chilean oncology specialist was designed to obtain qualitative information about 
their experience(s) with ipilimumab for the treatment of metastatic melanoma 
patients in Chile. RESULTS: Nineteen drugs met inclusion criteria with 28 advance 
cancer indications. The average cost per month of mean survival improvement was 
estimated at $24,802 (range 1,737 – $91,256). We estimated the cost per additional 
month of mean survival improvement at $13,122 and $14.843 for first and second 
line treatment with ipilimumab respectively. Based on the survey, local expert 
opinion unanimously stated that ipilimumab is the best treatment alternative for 
patients with advanced melanoma. CONCLUSIONS: Compared with other inno-
vative drugs for the treatment of advanced cancers, the cost per mean survival 
improvement with ipilimumab was below the average market value and may 
provide good value for money from a third payer perspective in Chile. Based on 
the survey, specialists noted ipilimumab as the best treatment option for Chilean 
patient with advanced melanoma.
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OBJECTIVES: In the ICON7 randomized controlled trial, Oza et al. reported that 
the 502 front line ovarian cancer patients who were at a high-risk of relapse, that 
is patients with stage III suboptimal debulking, stage III unresectable or stage IV 
disease, could benefit most effectively from the addition of bevacizumab (7.5mg/kg) 
to chemotherapy (carboplatin, paclitaxel), compared to chemotherapy alone in the 
front line setting. The objective of this study is to investigate the cost effectiveness 
(CE) of this proposed change in treatment practices. METHODS: Long-term PFS and 
OS were predicted using log-logistic time-to-event parametric functions over a time 
horizon of 10 years. Canadian PFS health state utility values were obtained from the 
mapping of EQ5D scores from ICON7’s high risk patient population. Post progression 
utility values were derived from Naik et al (2014) Canadian study. The cost inputs, 
including standard resource use practices, for this CE model were informed from 
public sources, gynecological oncology experts and ICON7. An annual 5% discount 
rate was applied to both efficacy and costs. A probabilistic sensitivity analysis (PSA) 
as well as one-way sensitivity analyses were conducted. RESULTS: The ICON7 high-
risk patients receiving bevacizumab plus chemotherapy had a mean LY gain of 5.8 
months compared to patients on chemotherapy alone, and a mean QALY gain of 
4.5 months. This resulted in an ICER of $74,084CAD per LY gained and $96,261CAD 
per QALY gained. 55% PSA simulation of the QALY ICERs were at $100,000CAD or 
less. CONCLUSIONS: Although no formal willingness-to-pay threshold exists for 
health technology assessments in Canada, $100,000CAD has been estimated for 
oncology drugs. At a $100,000CAD threshold, bevacizumab in addition to chemo-
therapy provides a cost-effectiveness alternative for high-risk patients (i.e. stage 
III suboptimal debulking, stage III unresectable or stage IV) with ovarian cancer in 
the front line setting.
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OBJECTIVES: This study examined indirect costs in terms of productivity loss 
among patients who received eribulin vs. other commonly used chemotherapies 
in the treatment of metastatic breast cancer (MBC). METHODS: The MarketScan 
Health and Productivity Management Database (2008-2012) was used. Patients 
who initiated eribulin, or received single-agent gemcitabine/capecitabine/vinorel-
bine as the last chemotherapy during the index period (July 2008-Nov 2012) 
were defined as each corresponding study cohort. Adult MBC patients eligible 
for ≥ 1 month employee benefits of short-term disability (STDI) were identified. 
Difference in STDI days was compared between study cohorts using Wilcoxon-
rank-sum-test. STDI-related costs were estimated by multiplying leave days by 
median weekly wages. Two-step generalized linear models were used to estimate 
adjusted indirect costs by controlling for age, payer, region, comorbidities, prior 
chemotherapy, and hormone therapy. RESULTS: A total of 43 patients receiving 
eribulin, 99 gemcitabine, 54 vinorelbine, and 303 capecitabine were eligible for 
STDI (mutually exclusive). Eribulin patients had either similar (vs. gemcitabine 
or vinorelbine) or more (vs. capecitabine) chemotherapy agents prior to initiat-
ing index treatment. Eribulin patients had either numerically lower or similar 
STDI days per-patient-per-month compared to those receiving other therapies 
(6.2±10.8 vs. 8.8±11.0 [gemcitabine], P= .055; 7.1±10.3 [vinorelbine], P= .201; 6.1±9.2 
[capecitabine], P= .295). In addition, eribulin (vs. gemcitabine) patients were less 
likely to have any STDI leave (30% vs. 53%, P= .014). The adjusted mean indirect 
costs associated with STDI per-patient-per-month were $720 (95% CI: $470-$1,102), 
$944 (95% CI: $595-$1,175), $837 (95% CI: $744-$1,198) and $635 (95% CI: $536-
$753) for eribulin, gemcitabine, vinorelbine and capecitabine patients, respec-
tively. CONCLUSIONS: Productivity loss, as measured by utilization of STDI and 
associated costs, tended to be lower in MBC patients treated with eribulin vs. 
gemcitabine and similar to vinorelbine or capecitabine.
